Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have lung cancer or 1–2 small cancer spots in the lung (called oligometastatic lesions) that are planned to be treated with a high-dose course of radiotherapy
- A confirmed cancer diagnosis through a tissue sample (biopsy) is strongly preferred, but may not always be required — if a biopsy is too risky, scans showing the tumour has grown over time or has features strongly suggesting cancer may be accepted (confirm with trial site)
- People who have been diagnosed with a scarring lung disease called fibrotic Interstitial Lung Disease (ILD) of any type, confirmed by a lung specialist and a central review panel
- People who are reasonably well and able to carry out some daily activities (a doctor-rated score of 0–3 on a standard health scale)
- People aged 18 or older
- People with a life expectancy of more than 6 months
- People who are already taking anti-fibrotic medicines (such as nintedanib or pirfenidone) and/or steroid tablets as part of their current ILD treatment may still be eligible — though some other immune-suppressing drugs must be stopped for 2 weeks before and after radiotherapy (confirm with trial site)
- People receiving standard chemotherapy at the same time may be eligible — though most other systemic treatments must be paused for 2 weeks before and after radiotherapy (confirm with trial site)
Who may not be able to join:
- People who have previously had radiotherapy to the lungs
- People currently taking steroid tablets or steroid infusions (intravenous corticosteroids)
- People who are planned to receive another local treatment to the same tumour area during the study (unless the cancer comes back)
- People with another medical condition that a doctor believes would make radiotherapy unsafe or make follow-up care not possible
- People who are currently pregnant
- Women of childbearing age who are not willing or able to use an effective form of contraception during the study (options include hormonal methods, an intrauterine device, barrier methods such as condoms, sterilisation of a partner, or abstinence)
- People who are currently breastfeeding
- People who are currently using, or have recently used, a supplement called NAC (N-Acetyl Cysteine)
- People who have a known allergy or previous bad reaction to either dexamethasone (a steroid medicine) or NAC
- People with a condition called scleroderma
- People with an active infection
- People with glaucoma (a condition affecting eye pressure)
- People with a mental health condition that could be made worse by taking dexamethasone
- People with a rare condition called cystinuria
- People with any other condition that the treating doctor believes makes dexamethasone or NAC unsafe for them
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Palma, MD, London Health Sciences Centre, Lawson Health Research Institute
Phone: 519-685-8650
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of Grade 2-5 Dyspnea within 6 Months Post Radiation Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.